WCLC 2025 - Posters & ePosters-EP.13.17 Efficacy of First-Line Chemoimmunotherapy With Durvalumab or Atezolizumab in SCLC - Experiences From Practice of Two Polish Oncology Centers

EP.13.17 Efficacy of First-Line Chemoimmunotherapy With Durvalumab or Atezolizumab in SCLC - Experiences From Practice of Two Polish Oncology Centers

Back to course

Pdf Summary

This retrospective study analyzed real-world outcomes of first-line chemoimmunotherapy using Durvalumab or Atezolizumab combined with chemotherapy (etoposide and platinum) in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated between 2021 and 2023 at two Polish oncology centers. The cohort included 152 patients treated with Durvalumab and 5,498 with Atezolizumab; all were smokers with good performance status and varied metastases presence (liver, CNS, bones).<br /><br />The study found similar disease control rates between the two treatments (Durvalumab: 85.2%, Atezolizumab: 84.7%), with comparable rates of partial response, stable disease, and progression. Median progression-free survival (PFS) was 6 months, and median overall survival (OS) was 11.5 months across all patients. Treatment choice and bone metastases did not significantly influence progression or death risk.<br /><br />However, metastases in the central nervous system (CNS) and liver were associated with significantly higher risks of disease progression and death. Specifically, CNS metastases increased the risk of progression (HR 1.54, p=0.0487) and death (HR 1.78, p=0.0168), while liver metastases significantly increased the risk of death (HR 1.97, p=0.0107).<br /><br />In conclusion, first-line chemoimmunotherapy with either Durvalumab or Atezolizumab appears effective for ES-SCLC patients in clinical practice, with no significant difference in efficacy between regimens. The presence of CNS and liver metastases stands out as critical adverse prognostic factors negatively impacting survival outcomes. These findings support the routine use of chemoimmunotherapy in ES-SCLC and highlight the need for careful management of patients with CNS and liver metastases to improve prognosis.

Asset Subtitle

Aleksandra Lomza-Laba

Meta Tag

Speaker Aleksandra Lomza-Laba

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

extensive-stage small-cell lung cancer

ES-SCLC

chemoimmunotherapy

Durvalumab

Atezolizumab

etoposide

platinum chemotherapy

central nervous system metastases

liver metastases

progression-free survival